Hereditary Angioedema Market Size, Share, Growth, and Industry Analysis, By Type (Type I HAE, Type II HAE, Type III HAE), By Application (Hospitals, clinics, Research centers), Regional Insights and Forecast to 2035

Hereditary Angioedema Market Overview

Global Hereditary Angioedema Market size is expected to grow from USD 4213.82 Million in 2026 to USD 9918.8 Million by 2035, registering a steady CAGR of 9.98%.

The Hereditary Angioedema Market Market is expanding as improved diagnosis, prophylactic therapies, oral medicines, and precision treatments transform management of this rare genetic disorder affecting approximately 1 in 50,000 people globally. Type I HAE represents approximately 85% of diagnosed cases, while Type II accounts for nearly 15%. Patients may experience attacks every 7 days or multiple times monthly, creating sustained demand for preventive and ondemand therapies. Approximately 50% of untreated patients may experience potentially dangerous laryngeal attacks during their lifetime. Increasing use of subcutaneous drugs, oral kallikrein inhibitors, monoclonal antibodies, and RNAtargeted therapies is strengthening the Hereditary Angioedema Market Market.

The USA represents the largest national treatment landscape for hereditary angioedema, supported by approximately 10,000 diagnosed patients and an estimated potential patient population exceeding 15,000 individuals. The condition affects approximately 1 in 50,000 Americans, while Type I HAE constitutes nearly 85% of diagnosed cases. More than 10 targeted preventive and ondemand treatment options have become available for different patient groups. The USA has accelerated adoption of oral prophylaxis, subcutaneous monoclonal antibodies, plasmaderived C1 inhibitors, and kallikreintargeted medicines. In 2025, 3 new HAE treatments received regulatory approval, significantly broadening therapeutic choice and reinforcing the country's leadership in advanced hereditary angioedema management.

What is Hereditary Angioedema Market

The Hereditary Angioedema Market covers medicines, diagnostic technologies, prophylactic therapies, ondemand treatments, and emerging genetic interventions used for a rare inherited swelling disorder affecting approximately 1 in 50,000 people. Type I accounts for about 85% of cases, with attacks affecting skin, abdomen, face, extremities, and potentially the upper airway.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: Approximately 85% of hereditary angioedema cases are Type I, while nearly 50% of untreated patients can experience laryngeal swelling during their lifetime, increasing preventivetreatment adoption by approximately 60% and supporting stronger demand for targeted prophylactic therapies.

• Major Market Restraint: Approximately 75% of patients experience diagnostic delays, while nearly 40% initially receive an incorrect diagnosis. Limited specialist access affects approximately 35% of underserved patients, restricting early treatment initiation and reducing effective diseasemanagement coverage in developing healthcare systems.

• Emerging Trends: Oral prophylactic therapies account for approximately 25% of treatment preference, while subcutaneous therapies represent nearly 45% of preventivetreatment adoption. Patient preference for selfadministration exceeds 60%, accelerating development of oral, monthly, and lessfrequent therapeutic options.

• Regional Leadership: North America holds approximately 46% of the global Hereditary Angioedema Market Market, Europe accounts for nearly 29%, AsiaPacific represents approximately 17%, and Middle East & Africa contributes close to 8%, reflecting differences in diagnosis and therapeutic access.

• Competitive Landscape: Leading manufacturers collectively account for approximately 65% of established HAE treatment adoption, while the top 2 companies represent an estimated 43% combined share. Innovative oral and injectable competitors increasingly challenge established plasmaderived and antibodybased therapies.

• Market Segmentation: Type I HAE represents approximately 85% of diagnosed patients, Type II accounts for nearly 15%, and recognized HAE with normal C1 inhibitor remains below 5% in many diagnosed cohorts, supporting differentiated genetic and biomarkerbased treatment strategies.

• Recent Development: Advanced prophylactic therapies have demonstrated attack reductions exceeding 80%, while investigational geneediting approaches have produced reductions above 90% in selected clinical studies. Oral treatments have increased therapeutic convenience by eliminating injections for approximately 100% of eligible administrations.

Hereditary Angioedema Market Latest Trends

The Hereditary Angioedema Market Market is moving rapidly toward oral administration, extended dosing intervals, RNAtargeted medicines, and onetime genetic interventions. Approximately 1 in 50,000 people globally has HAE, yet diagnosis remains delayed for many patients because attacks resemble allergic swelling, gastrointestinal disorders, or other conditions. Type I accounts for approximately 85% of cases, creating a concentrated patient population for C1inhibitor, kallikrein, and bradykinintargeted therapies.One major Hereditary Angioedema Market Market trend is the transition from frequent intravenous infusions toward oncedaily oral prophylaxis and subcutaneous administration. Oral preventive therapy can eliminate injection burden across 100% of scheduled doses for eligible patients.

Advanced antisense therapies have demonstrated attack reductions above 80%, while geneediting approaches have shown reductions exceeding 90% in selected clinical investigations.The therapeutic pipeline is also becoming more competitive. In 2025, the USA approved 3 new HAE treatments, substantially expanding preventive and ondemand options. Greater emphasis on pediatric access, selfadministration, rapid attack control, and personalized prophylaxis is reshaping prescribing behavior. Digital monitoring applications and artificial intelligence are additionally improving attack tracking, treatment adherence, patient identification, and clinicaltrial recruitment across the Hereditary Angioedema Market Market.

How does AI influence the Hereditary Angioedema Market

Artificial intelligence influences the Hereditary Angioedema Market Market by improving diagnosis, attack prediction, drug discovery, and patient identification. AIsupported algorithms can evaluate hundreds of clinical variables, genetic markers, medication histories, and swelling patterns. With approximately 75% of patients facing diagnostic delays in some settings, machine learning can support earlier specialist referral. AI also helps analyze clinicaltrial populations, optimize candidate selection, predict treatment response, and improve monitoring of approximately 100% of digitally recorded attack episodes.

Hereditary Angioedema Market Dynamics

DRIVER

Rising diagnosis and adoption of advanced prophylactic therapies.

The primary driver of the Hereditary Angioedema Market Market is expanding diagnosis combined with stronger uptake of longterm prophylaxis. HAE affects approximately 1 in 50,000 individuals, while Type I represents about 85% of patients. Approximately 50% of untreated individuals may experience at least 1 potentially lifethreatening laryngeal episode during their lifetime, making reliable access to ondemand medication essential. Modern prophylactic therapies can reduce attacks by more than 80% in eligible populations, fundamentally changing disease management. Oncedaily oral medicines, subcutaneous monoclonal antibodies, C1inhibitor replacement therapies, and RNAtargeted products are increasing treatment choice. Growing genetic testing also supports family screening because children of an affected parent have a 50% probability of inheriting the responsible genetic variant.

RESTRAINT

Diagnostic delays and limited treatment accessibility.

A major restraint in the Hereditary Angioedema Market Market is the persistent delay between symptom onset and confirmed diagnosis. Approximately 75% of patients may encounter delayed recognition in certain healthcare environments, while symptoms can initially be confused with allergic angioedema, appendicitis, gastrointestinal disease, or other conditions. Standard antihistamines, corticosteroids, and epinephrine generally do not address bradykininmediated HAE attacks, creating additional treatment complexity. Type I and Type II diagnosis requires appropriate complement testing, including C4 and C1inhibitor measurements, while HAE with normal C1 inhibitor may require genetic evaluation. Specialist availability remains uneven, particularly outside major urban centers. These barriers reduce treatment penetration among potentially undiagnosed patients and limit access to advanced prophylaxis across lowerresource regions.

OPPORTUNITY

Expansion of oral, RNAbased, and geneediting treatments.

The strongest Hereditary Angioedema Market Market opportunity lies in therapies that reduce treatment burden while providing sustained attack prevention. Oral prophylaxis already enables oncedaily administration for eligible patients aged 12 years and older with established products, while newer medicines are expanding age eligibility and dosing flexibility. RNAtargeted treatment has demonstrated attack reductions exceeding 80%, creating a new competitive therapeutic class. Gene editing offers another major opportunity, with investigational approaches reporting attack reductions exceeding 90% in selected study populations after a single treatment. Approximately 25% of HAE cases can result from spontaneous mutations rather than an inherited family history, highlighting the need for broader identification programs. 

CHALLENGE

Rare patient populations and complex clinical development.

The Hereditary Angioedema Market Market faces the fundamental challenge of recruiting sufficient patients for clinical trials because prevalence is approximately 1 in 50,000 individuals. Individual attack frequency varies significantly, with some patients experiencing several attacks annually and others facing multiple episodes every month. This heterogeneity complicates endpoint selection, comparative assessment, and treatmentresponse evaluation. Type I constitutes approximately 85% of cases, leaving much smaller populations for Type II and HAE with normal C1 inhibitor studies. Pediatric recruitment creates additional difficulties because symptoms may begin before age 10 but severity can change during puberty. Manufacturers must also demonstrate meaningful attack reduction, rapid symptom control, acceptable safety, convenient administration, and durable effectiveness against established therapies that already achieve reductions above 80%.

Why is the Hereditary Angioedema Market Industry experiencing rapid growth

The Hereditary Angioedema Market Industry is experiencing rapid growth because diagnosis is improving, prophylactic treatment is becoming more effective, and therapeutic convenience is increasing substantially. Approximately 1 in 50,000 people has HAE, while 50% of children with an affected parent may inherit the condition. Type I represents approximately 85% of cases, providing a clearly defined treatment population. New therapies have demonstrated attack reductions exceeding 80%, and selected investigational geneediting programs have reported reductions above 90%. In 2025 alone, 3 new treatments received USA regulatory approval, creating greater competition among oral, injectable, RNAtargeted, antibodybased, and ondemand products.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

Segmentation Analysis

The Hereditary Angioedema Market Market is segmented by type into Type I HAE, Type II HAE, and Type III HAE, while application segmentation includes hospitals, clinics, and research centers. Type I dominates with approximately 85% share because reduced C1inhibitor quantity represents the most common disease mechanism. Hospitals hold approximately 52% of treatment activity because severe abdominal and airway attacks frequently require emergency assessment. Clinics represent nearly 33%, driven by routine prophylaxis management and specialist consultations, while research centers account for approximately 15%, supported by more than 20 active or recently completed studies involving oral inhibitors, antibodies, RNA medicines, and genetic interventions.

By Type

Type I HAE: Type I HAE dominates the Hereditary Angioedema Market Market with approximately 85% market share based on diagnosed disease distribution. This subtype results primarily from deficient quantities of functional C1 inhibitor and is commonly associated with pathogenic variants in the SERPING1 gene. Patients can experience swelling of the extremities, face, abdomen, genital region, and upper airway. Approximately 50% of untreated patients may experience a laryngeal attack during their lifetime. Because Type I represents the largest identifiable population, it receives the greatest attention from manufacturers developing C1inhibitor replacements, kallikrein inhibitors, monoclonal antibodies, antisense therapies, and geneediting candidates. Genetic inheritance risk reaches 50% when 1 parent carries the causative variant.

Type II HAE: Type II HAE accounts for approximately 15% of hereditary angioedema cases and is characterized by normal or elevated quantities of C1 inhibitor with impaired functional activity. Although less prevalent than Type I, Type II creates significant therapeutic demand because patients can experience similarly painful abdominal, peripheral, facial, and potentially fatal airway attacks. Diagnostic evaluation generally requires functional C1inhibitor testing alongside C4 measurement because protein quantity alone can be misleading. Type II patients benefit from many of the same established therapies used for Type I disease, including C1inhibitor products, kallikrein inhibitors, bradykininreceptor antagonists, and preventive antibodies. Approximately 50% inheritance probability applies when an affected parent transmits the relevant autosomal dominant variant.

By Application

Hospitals: Hospitals lead the Hereditary Angioedema Market Market application segment with approximately 52% share, reflecting their central role in emergency treatment, specialist diagnosis, infusion services, and management of potentially fatal airway swelling. Laryngeal involvement represents the most dangerous manifestation, and approximately 50% of untreated patients may experience at least 1 such episode during their lifetime. Hospitals provide access to C1inhibitor concentrates, kallikrein inhibitors, bradykininreceptor antagonists, airway intervention, and multidisciplinary specialists. Large medical centers also conduct genetic testing and complement assays. Emergency departments remain critical because an untreated attack can progress over several hours, while abdominal attacks can cause severe pain, vomiting, dehydration, and unnecessary surgical procedures when HAE is unrecognized.

Clinics: Clinics account for approximately 33% of Hereditary Angioedema Market Market application share and are increasingly important for longterm prophylaxis, routine monitoring, family screening, patient education, and specialist consultation. Modern selfadministered treatments have shifted disease management away from repeated hospital visits. Oncedaily oral prophylaxis eliminates injection requirements for 100% of scheduled doses among eligible users, while subcutaneous medicines can also be administered at home. Clinics monitor attack frequency, adverse effects, adherence, and treatment effectiveness. Because children of an affected parent have a 50% inheritance probability, outpatient genetic counseling and family screening are particularly valuable.

Which segment is expected to witness the fastest growth

The research centers segment is expected to witness the fastest growth, with its participation potentially increasing by approximately 18% as geneediting, antisense, oral kallikrein, and monoclonalantibody pipelines expand. More than 20 clinical programs and studies have investigated innovative HAE mechanisms, while selected genetic therapies have demonstrated attack reductions exceeding 90%, supporting stronger research activity.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Hereditary Angioedema Market Regional Outlook

The global Hereditary Angioedema Market Market shows substantial regional variation in diagnosis, treatment availability, reimbursement, and specialist infrastructure. North America leads with approximately 46% share, supported by extensive regulatory approvals and approximately 10,000 diagnosed USA patients. Europe represents nearly 29%, driven by established raredisease networks and broad treatment access. AsiaPacific accounts for approximately 17%, with increasing diagnosis in Japan, China, Australia, and South Korea. Middle East & Africa holds approximately 8%, where specialist access remains concentrated in selected urban centers. Globally, HAE affects approximately 1 in 50,000 individuals, creating persistent opportunities for expanded genetic screening and prophylactic therapy.

North America

North America leads the Hereditary Angioedema Market Market with approximately 46% global share, driven primarily by the USA and supported by Canada. The region benefits from strong diagnosis infrastructure, specialized allergy and immunology centers, genetic testing, patient advocacy, clinicaltrial participation, and broad availability of targeted therapies. Approximately 10,000 people in the USA have a confirmed HAE diagnosis, while the potential affected population may exceed 15,000 individuals based on prevalence assumptions. Type I represents approximately 85% of cases, making C1inhibitor deficiency the dominant clinical category.The USA has approved multiple therapeutic mechanisms, including plasmaderived C1 inhibitors, recombinant C1 inhibitor, bradykininreceptor antagonists, plasma kallikrein inhibitors, monoclonal antibodies, oral prophylactic agents, and RNAtargeted medicines.

Europe

Europe accounts for approximately 29% of the global Hereditary Angioedema Market Market and maintains an established network of raredisease specialists, immunologists, genetic laboratories, and national referral centers. Major treatment markets include Germany, France, Italy, Spain, and the United Kingdom, where targeted C1inhibitor replacement, bradykinin antagonism, kallikrein inhibition, monoclonal antibodies, and oral prophylaxis are incorporated into specialist care. HAE affects approximately 1 in 50,000 people, meaning Europe's population supports a substantial potential patient pool despite underdiagnosis.European clinicians increasingly prioritize individualized prophylaxis based on attack frequency, severity, airway involvement, treatment burden, and patient preference. Type I HAE represents approximately 85% of cases, while Type II accounts for approximately 15%. 

AsiaPacific

AsiaPacific holds approximately 17% of the global Hereditary Angioedema Market Market, with growth supported by improving disease awareness, specialist education, genetic testing, and treatment availability in Japan, China, Australia, South Korea, and other healthcare systems. Based on the global prevalence estimate of approximately 1 in 50,000 people, the region contains a potentially large undiagnosed population. However, confirmed diagnosis remains substantially below theoretical prevalence in several countries because HAE can be confused with allergy, gastrointestinal illness, or idiopathic swelling.Japan has one of the region's most developed HAE treatment environments, offering access to targeted ondemand and prophylactic medicines. 

Middle East & Africa

Middle East & Africa accounts for approximately 8% of the global Hereditary Angioedema Market Market. The region has substantial unmet diagnostic need because specialist services, complement testing, genetic sequencing, and targeted medicines remain unevenly distributed. Based on an estimated prevalence of approximately 1 in 50,000 individuals, thousands of patients could remain unidentified across the region. Diagnostic delays are especially significant where recurrent swelling is incorrectly classified as allergy or where severe abdominal attacks lead to repeated emergency treatment without C4 or C1inhibitor testing.Advanced HAE services are concentrated in selected countries and major urban medical centers. Type I disease represents approximately 85% of diagnosed cases globally, while Type II contributes approximately 15%. 

List of Top Hereditary Angioedema Market Companies

• iBio
• Pharming Group
• BioCryst Pharmaceuticals
• Cipla, Inc.
• Ionis Pharmaceuticals
• Merck & Co., Inc.
• Sanofi N.V.
• Teva Pharmaceutical Industries

List of Top tow Companies Market Share

• Shire/Takeda: Approximately 29% market share, supported by a broad HAE portfolio covering prophylactic and ondemand treatment and strong adoption of monoclonalantibody prevention.

• CSL: Approximately 14% market share, supported by established C1inhibitor therapies and newer preventive innovation targeting Factor XIIa, giving the top 2 companies a combined estimated share of 43%.

Investment Analysis and Opportunities

Investment in the Hereditary Angioedema Market Market is increasingly directed toward oral medicines, extendedinterval injections, RNA silencing, gene editing, pediatric formulations, and digital disease management. The global prevalence of approximately 1 in 50,000 creates a defined raredisease population with significant unmet needs. Type I accounts for approximately 85% of diagnosed cases, concentrating investment around C1 inhibitor, plasma kallikrein, bradykinin, and Factor XII pathways.Geneediting programs represent one of the most transformative investment opportunities. Selected clinical studies have demonstrated attack reductions above 90% after a single intervention, potentially changing treatment from lifelong administration to durable disease control.

RNAtargeted therapy has separately achieved attack reductions exceeding 80%, validating another major platform.Oral administration is also attracting substantial investment because it removes needles from 100% of scheduled doses for eligible users. The approval of 3 new HAE treatments in the USA during 2025 demonstrates increasing regulatory momentum and therapeutic diversification. Additional opportunities exist in pediatric indications, genetic diagnostics, artificial intelligencesupported patient identification, and expansion into underserved regions. Family screening is commercially and clinically important because every child of an affected parent carries a 50% inheritance probability, enabling earlier identification and preventive intervention.

New Product Development

New product development in the Hereditary Angioedema Market Market is focused on convenience, speed, durability, and personalized prevention. The therapeutic landscape now includes oral prophylaxis, oral ondemand treatment, subcutaneous antibodies, antisense oligonucleotides, Factor XIIa inhibition, and CRISPRbased gene editing. Modern prophylactic medicines can reduce attacks by more than 80%, while selected experimental genetic interventions have demonstrated reductions exceeding 90%.Oral innovation has become particularly important because injections and intravenous infusions create treatment burden. Oncedaily oral prophylaxis can eliminate injections for 100% of preventive doses among eligible users.

New oral ondemand medicines are also designed to allow treatment immediately after patients recognize attack symptoms.RNAtargeted products suppress production of diseaserelated proteins, with advanced therapies demonstrating approximately 81% attack reduction compared with placebo in pivotal research. Extendedinterval injectable medicines are being developed to reduce administration frequency to 1 dose every several months. Geneediting therapies aim to permanently modify liverbased kallikrein pathways following a single administration.

Five Recent Developments (20232025)

• October 2023: BioCryst Pharmaceuticals expanded the international reach of its oncedaily oral HAE prophylactic therapy, strengthening access across additional markets. The medicine is intended for eligible patients aged 12 years and older and eliminates injection requirements for 100% of scheduled preventive doses, supporting increased patient preference for oral administration.
• January 2024: Intellia Therapeutics reported encouraging longterm results for its investigational CRISPRbased HAE therapy, with selected patients demonstrating attack reductions exceeding 90%. The singledose approach targets the kallikrein pathway and represents a potential shift away from lifelong preventive administration toward durable genetic intervention after only 1 treatment.
• May 2024: KalVista Pharmaceuticals advanced regulatory submissions for sebetralstat, an oral ondemand treatment designed for HAE attacks. Clinical development included more than 100 patients and demonstrated faster symptom relief than placebo, supporting the possibility of eliminating injections from 100% of treated attacks among eligible patients using the oral therapy.
• September 2024: CSL advanced garadacimab, a monoclonal antibody targeting activated Factor XII, after Phase 3 evidence demonstrated substantial reductions in monthly HAE attack rates. The medicine introduced a distinct preventive mechanism and monthly administration approach, adding competition to established kallikrein inhibitors and C1inhibitor therapies.
• February 2025: Ionis Pharmaceuticals continued regulatory advancement of donidalorsen following Phase 3 results showing an approximately 81% reduction in HAE attack rates compared with placebo. The RNAtargeted therapy was designed for extended dosing intervals and strengthened the emerging antisense segment of the Hereditary Angioedema Market Market.

Report Coverage of Hereditary Angioedema Market

The Report Coverage of Hereditary Angioedema Market Market evaluates disease prevalence, therapeutic adoption, diagnosis, patient segmentation, treatment mechanisms, regional performance, company positioning, investments, product development, and clinical innovation. The analysis covers 3 major disease classifications: Type I HAE, Type II HAE, and Type III HAE or HAE with normal C1 inhibitor. Type I represents approximately 85% of cases, while Type II accounts for approximately 15%.Application coverage includes hospitals with approximately 52% share, clinics with nearly 33%, and research centers with approximately 15%. Regional analysis covers North America at approximately 46%, Europe at 29%, AsiaPacific at 17%, and Middle East & Africa at 8%.

The report examines established and emerging treatment classes including C1inhibitor replacement, bradykininreceptor antagonists, plasma kallikrein inhibitors, monoclonal antibodies, oral prophylactic therapies, antisense medicines, and geneediting interventions. It also evaluates the influence of more than 20 clinical research programs and studies addressing attack prevention, rapid symptom control, pediatric access, and durable treatment.Competitive coverage includes 10 identified companies active or strategically relevant to rare diseases and HAErelated pharmaceutical development. The report emphasizes the approximately 1in50,000 global prevalence, 50% inheritance probability from an affected parent, attack reductions exceeding 80% for advanced prophylaxis, and emerging genetic interventions demonstrating reductions above 90% in selected clinical studies.

Hereditary Angioedema Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 4213.82 Billion in 2026
Market Size Value By	USD 9918.8 Billion by 2035
Growth Rate	CAGR of 9.98% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Type I HAE Type II HAE Type III HAE By Application : Hospitals clinics Research centers
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample